StreetAlpha.app
Home › Stocks › JAZZ

Jazz Pharmaceuticals plc (JAZZ)

Healthcare
$240.71
▲ +0.39%
LAST CLOSE · NOV 17

Jazz Pharmaceuticals develops and sells medicines for rare diseases, including sleep disorders, epilepsy and cancer. It last closed at $240.71 on Nov 17, up 0.39% on the day. JAZZ last reported earnings on Mon, Nov 2, 2026. The average 12-month price target from 11 analysts is $312.64 (+29.9% from the last close), with a high of $337.00 and a low of $275.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (11 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in JAZZ, 50% of them bullish and 50% bearish. In the past 30 days there were 9 dark pool prints totaling $9.1M, the largest $2.9M.

AI Auto Pilots
Is JAZZ in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$4.7B
+13.5% vs a year ago
Net income
$206.0M
4.4% margin
EPS (diluted)
$3.38
Free cash flow
$1.6B
34.4% margin
Valuation
Market cap
$15.5B
64.2M shares
P/E
71.2
Price over 12 month EPS
Price to sales
3.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.0B
At Sep 30
Debt
$5.6B
At Sep 30
Shareholder equity
$4.2B
Buybacks
$225.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.1B$3.1BFY2021FY2022: $3.7B$3.7BFY2022FY2023: $3.8B$3.8BFY2023FY2024: $4.1B$4.1BFY2024FY2025: $4.3B$4.3BFY2025

From JAZZ's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Last report
Nov 2
2026 · After the close (AMC)
Reported EPS
-$4.83
vs -$5.18 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±7.9%
Priced in before that report
Analyst consensus
Strong Buy
Based on 11 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
11firms
11 Buy0 Hold0 Sell
Each firm's latest rating on JAZZ in the past 90 days
Average 12-month target
$312.64
▲ 29.9% upside

Based on 11 analysts who set a price target on JAZZ in the past 90 days. The average target is $312.64, with a high of $337.00 and a low of $275.00, compared with the last close of $240.71.

Low $275.00Avg $312.64High $337.00
Blue marker: last close $240.71
Highest target$337.00
Average target$312.64
Lowest target$275.00
Latest rating changes
Morgan StanleyTarget raised
Nov 13Buy$319 → $324
Piper SandlerTarget raised
Nov 12Buy$310 → $330
JP MorganTarget raised
Nov 3Buy$300 → $310
Morgan StanleyTarget raised
Nov 3Buy$314 → $319
RBC CapitalTarget raised
Nov 3Buy$296 → $305
DateFirmActionRatingPrice target
Nov 13Morgan StanleyTarget raisedBuy$319 → $324
Nov 12Piper SandlerTarget raisedBuy$310 → $330
Nov 3JP MorganTarget raisedBuy$300 → $310
Nov 3Morgan StanleyTarget raisedBuy$314 → $319
Nov 3RBC CapitalTarget raisedBuy$296 → $305
Loading…

Technical Analysis

JAZZ · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 6% above its 20 day and 5% above its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60), near overbought. The nearest support is the swing low (Aug 14) at $240.63, and the nearest resistance the swing high (Jun 5) at $241.99.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 3.0%/day
Key levels
$266.3852 week high+10.7%
$242.77Pivot R1+0.9%
$241.99Swing high (Jun 5)+0.5%
$240.71Last close
$240.63Swing low (Aug 14)−0.0%
$240.32Pivot−0.2%
$239.04100 day average−0.7%
$238.25Pivot S1−1.0%
$229.0050 day average−4.9%
$226.1320 day average−6.1%
$220.77200 day average−8.3%
$156.9552 week low−34.8%
Indicators
RSI (14)59.66Middle of its rangeNeutral
MACD5.36Above its signal lineBullish
Stochastic80.0Near the top of its rangeOverbought
ADX (14)31.7Trending up
Williams %R-20.9Oversold below −80, overbought above −20Neutral
CCI (20)71.1Oversold below −100, overbought above 100Neutral
Rate of change+4.8%Change over 10 sessionsBullish
ATR (14)$7.25Typical daily range, 3.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for JAZZ

What happened before

See how JAZZ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow JAZZ usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How JAZZ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Oct 22 – Nov 3
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
9
Notional
$9.1M
Largest print
$2.9M
Loading…

JAZZ Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲366 buying vs 278 selling
  • ▲Held by funds +1.0 pts
  • ▲Funds holding +22
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding669647+3.4%
In funds' top 101114−21.4%
Held by funds101.4%100.4%+1.0 pts
New / increased104 / 262129 / 243−1.6%
Reduced / sold out203 / 75184 / 57+15.4%
Put/call ratio0.111.07−90.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See JAZZ institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JAZZ is in one of them and how their past JAZZ trades turned out.

JAZZ in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered JAZZ in an article yet. Here's the latest on the wider market.

JAZZ Congress Trades

All congress trades →
Trades, 12 months
1
Buys
0
0%
Sells
1
100%
People
1
Last filed Dec 19
Who traded JAZZ · since 2018
Latest 5 filings of 10
$50K – $100KTraded Sep 10, 2025Filed Dec 19, 2025
$15K – $50KTraded Jul 12, 2023Filed Aug 13, 2023
$1K – $15KTraded May 19, 2023Filed Jun 12, 2023
$15K – $50KTraded Mar 6, 2023Filed Apr 17, 2023
$1K – $15KTraded Mar 14, 2023Filed Apr 7, 2023
PersonTypeAmountTradedFiledDelay
Bryan BedfordExecutive branchSell$50K – $100KSep 10, 2025Dec 19, 2025100 d
Dan GoldmanD · NYSell$15K – $50KJul 12, 2023Aug 13, 202332 d
Ro KhannaD · CASell$1K – $15KMay 19, 2023Jun 12, 202324 d
Dan GoldmanD · NYBuy$15K – $50KMar 6, 2023Apr 17, 202342 d
Ro KhannaD · CABuy$1K – $15KMar 14, 2023Apr 7, 202324 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is a biopharmaceutical company based in Dublin, Ireland. It develops and sells medicines for rare diseases, many of which have few or no existing treatment options. Its products include treatments for narcolepsy and other sleep disorders, medicines for certain forms of epilepsy, and cancer therapies. Its medicines are used by patients and prescribed by physicians in countries around the world.

Headquarters
Dublin
Founded
2003